transthyretin amyloid cardiomyopathy
Cardiovascular · 2020–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tafamidis Treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) with NYHA class I-II heart failure. | Mar 2026 | Noted | input received Cardiomyopathy Australia · Australian Amyloidosis Network |
| tafamidis Treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with evidence of cardiac involvement by echocardiography and with a history of heart… | Jul 2020 | Not recommended | 10 individuals |
Who spoke
Cardiomyopathy Australia · Australian Amyloidosis Network
What the PBS pays
$137M in government benefit over 2024–25, across 13,685 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tafamidis | $137.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.